Liraglutide

Liraglutide is an injectable medication that acts like GLP-1, a natural gut hormone released after eating. It slows stomach emptying, curbs appetite, and prompts the pancreas to release insulin when blood sugar is high ²⁹. It is approved in two forms: Victoza for type 2 diabetes (up to 1.8 mg daily) and Saxenda for chronic weight management (3.0 mg daily) ³⁸.

The drug traces back to exendin-4, a peptide found in Gila monster venom. Researchers used that template to build a version of human GLP-1 with a fatty-acid anchor that makes it last long enough for a single daily injection ²⁹.

What it is studied for

• Obesity and overweight: large trials and meta-analyses support the 3.0 mg daily weight-management dose ¹.
• Type 2 diabetes: RCTs show HbA1c reductions of roughly 1.6 to 1.8 percentage points ³⁰.
• Heart protection in diabetes: the LEADER trial found fewer major cardiovascular events and deaths ³.
• Fatty liver (MASLD): biopsy and imaging studies show improvements in steatohepatitis and liver fat ¹⁷.
• Brain and behavior: early-phase work examines Alzheimer's disease, Parkinson's risk, bipolar disorder weight gain, and opioid or alcohol craving ⁶.

Liraglutide turns on the GLP-1 receptor, the same switch the body's own GLP-1 hormone uses. GLP-1 is an incretin, a hormone released from the gut after a meal. Activating its receptor produces three effects that explain most of what liraglutide does ²⁹.

• Insulin release on demand. It amplifies insulin secretion from pancreatic beta cells, but only when blood glucose is elevated. That is why liraglutide alone rarely causes hypoglycemia, meaning low blood sugar ⁴³.
• Slower stomach emptying. Food leaves the stomach more gradually, which produces early fullness and drives much of the nausea seen during early titration ²⁸.
• Reduced appetite. GLP-1 receptors in brain regions including the hypothalamus and reward circuitry lower food intake and the appeal of high-value foods ¹⁵.

Fatty-acid acylation, a chemical anchor added to the peptide, slows its breakdown enough for once-daily dosing, unlike short-acting exenatide ²⁹.

Secondary mechanisms

• Reward circuitry: it blunts alcohol-induced dopamine release in the nucleus accumbens in animal models ¹⁶, and a small trial reported about a 40% reduction in opioid craving ¹⁵.
• Gut-brain axis: antidepressant-like effects in mice involve Lactobacillus changes and endocannabinoid signaling, independent of the GLP-1 receptor itself ⁴⁸.
• Neuroprotection: it lowers beta-amyloid processing enzymes and oxidative stress in hippocampal cells ⁴⁹. In the phase 2b ELAD trial, the primary endpoint was missed but an executive function measure improved ⁶.
• Cardiovascular tissue effects: animal work shows reduced endothelial-monocyte adhesion, less inflammatory macrophage signaling in sepsis, and lower atrial fibrillation burden tied to adiponectin in epicardial fat ⁵⁰.
• Autophagy and mitochondria: it restores cellular cleanup pathways in fatty liver, kidney podocytes, and diabetic cardiomyopathy models ⁵³.

Liraglutide's documented effects fall into metabolic, cardiovascular, liver, and neuro-behavioral domains.

Weight and body composition

• A living network meta-analysis of 69 RCTs places liraglutide above placebo for weight loss ¹.
• The 3.0 mg daily dose produces average losses of roughly 8.8 to 11% of body weight ⁵.
• Diabetes status matters: non-diabetic users lost about 15.7% at 12 months versus 5.1% in diabetic users ⁸.
• Fat loss dominates, but lean mass also drops by about 1.54 kg versus placebo; exercise blunts that loss ⁹.
• In a real-world Taiwanese cohort at a mean dose of 1.4 mg daily, 76.7% achieved at least 5% loss by week 26, with systolic blood pressure down about 10 mmHg ⁴.

Glycemic and cardiovascular

• In type 2 diabetes, 1.8 mg daily lowers HbA1c by roughly 1.6 to 1.8 percentage points ³⁰.
• LEADER showed fewer major adverse cardiovascular events and deaths, and transportability analysis supports similar real-world effects ³.

Liver

• The biopsy-based LEAN trial reported steatohepatitis resolution without fibrosis worsening in 39% versus 9% with placebo ¹⁷.
• A 3-month prospective study showed liver fat measured by CAP score falling from 305 to 268 dB/m ¹⁸.

Brain and behavior

• The ELAD phase 2b trial in Alzheimer's disease missed its primary endpoint, but one cognitive measure improved ⁶.
• A Scandinavian cohort found a 19% lower Parkinson's disease incidence versus sulfonylurea users ²⁴.
• In stable bipolar disorder, a 40-week RCT found significant weight loss and reduced binge eating ⁷.
• A small trial reported about 40% lower opioid craving ¹⁵; alcohol-reduction evidence is preclinical only ¹⁶.

Every liraglutide protocol uses once-daily subcutaneous injections and starts at 0.6 mg, then escalates in 0.6 mg weekly steps ⁴. The target dose depends on the indication.

Indication	Target dose	Typical duration
Obesity (Saxenda regimen)	3.0 mg daily	56 weeks or longer
Type 2 diabetes (Victoza regimen)	1.2-1.8 mg daily	Indefinite
Real-world obesity practice	Mean 1.4 mg daily	26 weeks typical

Dosing is not weight-adjusted; the same titration is used across body sizes in trials and real-world cohorts ⁴.

Titration is driven by GI tolerance. Nausea is the dose-limiting event at each step, and escalation is slowed or held when symptoms persist. A three-arm RCT found that 1.8 mg daily produced significantly greater BMI and body-fat reductions than 0.6 mg or 1.2 mg ⁶⁰. Real-world prescribing often plateaus at 1.2 to 1.8 mg: in one Taiwanese study, medication cost rather than tolerability kept the mean dose near 1.4 mg ⁴.

Response is usually assessed around weeks 12, 26, and 52. By week 13, typical weight loss is about 5.7 kg, reaching about 8.5 kg at week 26, with 76.7% achieving at least 5% loss ⁴. Patients awaiting bariatric surgery lost about 14 kg at 52 weeks ²³.

Marketed liraglutide (Victoza, Saxenda, and biosimilars) comes as a ready-to-use solution in prefilled pens, so clinical use needs no reconstitution ³⁰. Research-grade lyophilized (freeze-dried) liraglutide is different: it is reconstituted by adding bacteriostatic water (0.9% benzyl alcohol), the same practice used for most research peptides. Single-use preparations may use sterile water instead.

Mixing must be done gently. Liraglutide is aggregation-prone: combined air-water and silicone-oil-water stress triggers fibrillation, a process in which the peptide clumps into fiber-like aggregates. Swirl gently to dissolve, and never vortex or shake ³¹. High-pressure NMR and infrared spectroscopy both detect the structural changes that mark early degradation ⁸⁹.

Storage and shelf life

• Lyophilized powder: long-term at -20°C, or 2-8°C for short periods, protected from light and moisture.
• Reconstituted solution: refrigerate at 2-8°C and use within 30 days. Discard sooner if the solution is cloudy, gelled, or shows particles ³¹.
• Prefilled pens: refrigerate before first use; after first use they may be kept up to 30 days at room temperature or refrigerated. Never freeze.

The exact dilution and dose volumes depend on the vial size and target dose. Use the calculator in this section to work out the numbers for a specific preparation; the gentle-handling and storage rules above apply regardless of concentration.

Liraglutide slows gastric emptying and adds to glucose-dependent insulin signaling, so most clinically relevant interactions follow from those two effects.

Drug interactions

• Insulin and sulfonylureas: hypoglycemia risk rises mainly when liraglutide is combined with these agents. In the IDegLira fixed-ratio trial, pairing liraglutide with insulin degludec delivered greater HbA1c reduction (1.9% vs 0.9%) at the same insulin dose with comparable hypoglycemia ⁶⁵. Adding liraglutide to basal insulin beat adding mealtime insulin on glycemia and caused less hypoglycemia ⁸¹. Community practice reduces basal insulin 10-20% and halves the sulfonylurea dose at initiation.
• DPP-4 inhibitors: these share the same incretin pathway, so the combination is redundant and generally avoided.
• SGLT2 inhibitors: complementary mechanisms. In diabetic mice, liraglutide plus dapagliflozin beat either drug alone on glycemia, lipids, and beta-cell mass ⁸⁴. Both agents lower circulating volume, and GI fluid losses can compound that effect.
• Oral drugs with narrow absorption windows: slowed gastric emptying can delay absorption of levothyroxine, oral contraceptives, and warfarin. Separate dosing is standard practice.
• Anesthesia and sedation: the FDA added a warning about residual stomach contents and pulmonary aspiration during deep sedation or general anesthesia ⁶⁷. Individualized perioperative management is favored over routine discontinuation ²⁷.

Supplement interactions

• Ketogenic and very-low-carb diets: a case report documented starvation ketoacidosis on liraglutide plus a strict low-carbohydrate diet ³⁵. Avoid strict ketosis during treatment.
• Vitamin D: 12.4% of pediatric users developed a new vitamin D deficiency within a year, so repletion is standard monitoring practice ²¹.
• Hoodia gordonii: in rats, adding Hoodia extract to liraglutide was associated with near-normal kidney histology versus damage with liraglutide alone; human relevance is unknown ⁸⁶.

Liraglutide was studied and approved for continuous daily use, and no trial has tested deliberate on-off cycling. The patterns below combine the labeled titration with real-world usage reports.

What continuous use shows

• Persistent users achieved HbA1c reductions of 0.80% versus 0.32% in discontinuers ⁸⁷.
• Adolescent continuers showed a BMI change of -6.7% versus -0.7% in discontinuers, and weight trends back toward baseline after stopping ⁶⁹.
• Structured lifestyle therapy raised continuation odds 18.5-fold ⁶⁹.

Patterns that appear in practice

• 12-week block: real-world losses average about 5.7 kg by week 13, a common early reassessment point ⁴.
• 6-month block: about 8.5 kg at week 26, with 76.7% reaching at least 5% loss ⁴.
• Resensitization break: a 2-4 week pause after a plateau, followed by restarting at 0.6 mg and re-titrating weekly. GI tolerance fades within days of stopping, so restarting at full dose predictably re-triggers nausea.
• Perioperative hold: individualized holds around procedures requiring anesthesia ²⁷.

The restart rule in practice: after any gap of 3 days or more, start again at 0.6 mg and step up weekly. Breaks are typically cost-rationing or plateau management rather than receptor-driven, since GLP-1R signaling does not show classic tachyphylaxis.

Liraglutide is approved and studied mostly as monotherapy, but a few combinations have real data behind them.

• With insulin: the only routine peptide co-formulation is IDegLira, a fixed-ratio combination of insulin degludec and liraglutide. The liraglutide component adds incretin-driven glucose control with less hypoglycemia at an equivalent insulin dose ⁶⁵.
• With SGLT2 inhibitors: mechanistically complementary and synergistic in diabetic mice ⁸⁴. Watch volume status, since both agents reduce effective circulating volume.
• With other GLP-1 receptor agonists: never combined. Semaglutide, tirzepatide, and dulaglutide hit the same receptor, and stacking only compounds GI side effects. Switching between agents is standard: in post-bariatric regain, 12 months of liraglutide 3.0 mg recovered about 99% of regained weight, with semaglutide somewhat greater ²².
• With GH secretagogues (CJC-1295, ipamorelin, tesamorelin): no interaction data. There is a theoretical tension, since liraglutide reduces lean mass by about 1.54 kg in meta-analysis ⁹ while GH-pathway peptides aim to preserve or build muscle.
• With BPC-157 or TB-500: no published data. Community stacks that add BPC-157 for GI protection during GLP-1 titration are speculative.
• With Hoodia gordonii: animal data suggest a renoprotective interaction in an obesity model, but this has not been verified in humans ⁸⁶.

The ACP places liraglutide third-line for obesity behind semaglutide and tirzepatide, so many prescribers switch rather than stack ².

Liraglutide is FDA-approved under two labels ⁴³:

Product	Indication	Dose range
Victoza	Type 2 diabetes	1.2-1.8 mg daily
Saxenda	Chronic weight management	3.0 mg daily

The EMA authorized Victoza in 2009 and Saxenda in March 2015 ³⁸. Both regulators approve use in adolescents 12 and older with obesity ¹⁹. In the UK, NICE appraisal TA664 governs NHS Saxenda use ¹⁰⁷; Canada's CADTH reviewed Saxenda but recommended against public reimbursement ¹⁰².

Liraglutide is not a controlled substance. Supply is a live issue: shortages and cost have pushed users toward unregulated sources, and falsified Saxenda products have been documented ²⁸. Off-label GLP-1 prescribing without an approved indication rose 15-fold from 2021 to 2025, and 35.1% of off-label users had a normal BMI ³⁷.

WADA's position on liraglutide is not addressed in the reviewed literature, and no athlete sanctions were identified. In 2024 the FDA added a class-wide label warning about pulmonary aspiration during anesthesia or deep sedation due to residual stomach contents ⁶⁷.

GI side effects dominate the profile and peak during the first 4-6 weeks of titration. Across trials, nausea ranged from 14.7-62%, vomiting from 3-30.3%, and diarrhea from 5-34.9%, with all-cause discontinuation below 15% ⁵.

Key risks

• Pancreatitis: rare. Pooled phase 2/3 data showed 1.6 versus 0.7 cases per 1,000 patient-years, with other risk factors common; the UK audit found 0.027 per 100 patient-years ¹⁴.
• Gallbladder: real-world cohort data did not find a significant liraglutide-specific gallstone increase, though rapid weight loss raises biliary risk class-wide ¹³.
• Medullary thyroid cancer: a pharmacovigilance signal (ROR 41.1) underlies a boxed warning and the contraindication in people with MTC or MEN2 family history ¹².
• Optic neuropathy (NAION): a weaker signal than semaglutide (HR 1.251 vs 1.538), with low absolute risk ¹⁰.
• Mood: reporting signals for depressed mood and suicidal thoughts are concentrated in antidepressant-treated patients and early treatment, with a median time to onset of 96 days ²⁵.
• Kidney: acute kidney injury usually follows severe GI fluid losses rather than direct drug toxicity ⁷⁸.
• Stomach emptying: case reports of acute gastroparesis exist ³⁶.
• Rare reports: injection-site hypersensitivity and bullous pemphigoid ³³, starvation ketoacidosis on strict low-carb diets ³⁵, and hepatocellular injury on rechallenge ⁷⁵.

Monitoring in research

Baseline labs include HbA1c, glucose, creatinine/eGFR, ALT/AST, and lipids. Symptomatic lipase checks for pancreatitis, mood screening in the first 3 months for at-risk patients, and pediatric vitamin D monitoring are common practice ²¹. Stop treatment if pancreatitis is suspected.